BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA

NEXT STORY
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
PREV STORY
Zomedica Announces Management Changes
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA

NEXT STORY
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
PREV STORY
Zomedica Announces Management Changes
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4%

author_avatar
NASDAQ Market News

NewYork-Presbyterian Among Nation’s Best in Every Specialty Featured in U.S. News and World Report “Best Children’s Hospitals” Survey

New York, NY, June 26, 2018 (GLOBE NEWSWIRE) -- For the 12th year in ...

author_avatar
NASDAQ Market News

Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins

STAMFORD, Conn., May 12, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

author_avatar
NASDAQ Market News